This deep review covers the 2025–2026 performance and outlook for Blue Cross Blue Shield of Michigan (BCBSM), focusing on financial health, member sentiment, and upcoming changes.
BCBSM has moved to restrict coverage for popular GLP-1 weight-loss medications like Zepbound, Wegovy, and Saxenda for most commercial fully insured groups. bcbs of mi
For 2026, BCBSM has filed for a significant average rate increase of 18.1% for individual products . Key drivers include rising medical and pharmaceutical price trends (5.8%) and the expiration of ARPA subsidies (4.2%). This deep review covers the 2025–2026 performance and
Despite recent losses, BCBSM maintains an AM Best rating of A (Excellent) , indicating a high level of financial strength and ability to meet ongoing insurance obligations. Key drivers include rising medical and pharmaceutical price
Providers can request a peer-to-peer review with a BCBSM medical director within seven business days of a denial to discuss clinical necessity.
